Eli Lilly And Co (NYSE:LLY) – Cantor Fitzgerald issued their FY2020 earnings per share estimates for Eli Lilly And Co in a research report issued on Thursday, June 20th, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings per share of $6.50 for the year. Cantor Fitzgerald has a “Buy” rating and a $143.00 price objective on the stock.
LLY has been the topic of several other research reports. Goldman Sachs Group set a $27.00 target price on Melco Resorts & Entertainment and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Barclays restated a “buy” rating and set a $140.00 target price on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research report on Tuesday, April 23rd. Guggenheim increased their target price on Intuit from $260.00 to $310.00 in a research report on Thursday, April 11th. Finally, Bank of America set a $129.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Ten investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $119.99.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.01. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.31 earnings per share.
Large investors have recently made changes to their positions in the company. Athena Capital Advisors LLC bought a new position in shares of Eli Lilly And Co during the fourth quarter valued at about $26,000. Wakefield Asset Management LLLP bought a new position in shares of Eli Lilly And Co during the fourth quarter valued at about $27,000. Trust Department MB Financial Bank N A grew its stake in shares of Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after buying an additional 82 shares during the last quarter. Larson Financial Group LLC bought a new position in shares of Eli Lilly And Co during the fourth quarter valued at about $29,000. Finally, Acima Private Wealth LLC bought a new position in shares of Eli Lilly And Co during the fourth quarter valued at about $33,000. 79.37% of the stock is currently owned by hedge funds and other institutional investors.
In other Eli Lilly And Co news, VP Michael J. Harrington sold 16,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Christi Shaw sold 7,577 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $117.14, for a total value of $887,569.78. Following the sale, the senior vice president now owns 500 shares in the company, valued at approximately $58,570. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.645 per share. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.38%. Eli Lilly And Co’s payout ratio is 46.49%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: What is meant by a buy rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.